Literature DB >> 6247946

Sustained remission of Cushing's disease with mitotane and pituitary irradiation.

D E Schteingart, H S Tsao, C I Taylor, A McKenzie, R Victoria, B A Therrien.   

Abstract

Low doses of mitotane were given orally to 36 patients with Cushing's disease, concurrently with or after pituitary cobalt irradiation. Clinical and biochemical remission occurred in 29. The response to treatment occurred early in 17 patients and late in 12. The different pattern of response to mitotane was not related to the dose given or to its serum level. Early biochemical indicators of adrenal suppression with mitotane were a sharp decrease in adrenal response to the infusion of ACTH and in plasma levels of dehydroepiandrosterone sulfate. Although mitotane was given together with pituitary irradiation, initial remission was due mainly to the adrenal effect of mitotane. Plasma ACTH levels were still elevated when cortisol had returned to normal. In seventeen of the 29 patients who responded to treatment drug therapy has been discontinued, and they remain in remission of Cushing's syndrome. Side-effects have been dose dependent, with anorexia, nausea, decreased memory, and gynecomastia in men being the commonest.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247946     DOI: 10.7326/0003-4819-92-5-613

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  24 in total

Review 1.  Cushing's syndrome in children and adolescents: current diagnostic and therapeutic strategies.

Authors:  M A Magiakou; G P Chrousos
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

Review 2.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.

Authors:  Rosario Pivonello; Rosario Ferrigno; Maria Cristina De Martino; Chiara Simeoli; Nicola Di Paola; Claudia Pivonello; Livia Barba; Mariarosaria Negri; Cristina De Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

Review 3.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 4.  Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 5.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 6.  Medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 7.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

8.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Authors:  Beverly Mk Biller; Annamaria Colao; Stephan Petersenn; Vivien S Bonert; Marco Boscaro
Journal:  BMC Endocr Disord       Date:  2010-05-17       Impact factor: 2.763

9.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

10.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.